Anti-PD1 antibody therapy has become the first-line therapy for most patients with NSCLC either as monotherapy for PD-L1-high tumors or in combination with conventional chemotherapy for PD-L1-low tumors. The gene discussed is CD274; the disease is non-small cell lung carcinoma.